A5225: Phase I/II Dose-Finding Study of High-Dose Fluconazole Treatment in AIDS-Associated Cryptococcal Meningitis
Study Location:
India
Topic:
HIV
Clinicaltrials.gov Link:
https://clinicaltrials.gov/ct2/show/NCT00885703?term=A5225&rank=1
IRB#:
NA_00031152
Coordinator:
Nishi Suryavanshi
Enrollment:
Closed
Trial Period:
Completed
A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an induction-consolidation strategy of high-dose fluconazole alone for the treatment of cryptococcal meningitis (CM) in HIV-infected participants.
HIV-infected males and females ≥16 years of age presenting with their first episode of CM. Participants may not have received any antiretroviral treatment (ART) within 30 days prior to entry.